Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Gentien

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Journal of Hematology & Oncology|September 9, 2021
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breastIvan Bièche, Florence Coussy, Rania El-Botty, et al.
The Journal of Pathology|June 8, 2018
The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancersSandrine Tury, Franck Assayag, Florian Bonin, et al.
The Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.
Acta Neuropathologica|March 9, 2019
SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variationMaud Blanluet, Julien Masliah-Planchon, Irina Giurgea, et al.
Pigment Cell & Melanoma Research|February 1, 2017
Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenograftsRonan Crépin, David Gentien, Angeline Duché, et al.
BMC Cancer|June 3, 2011
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPatricia de Cremoux, Fabien Valet, David Gentien, et al.
Cancers|January 21, 2022
PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast CancerSamyuktha Suresh, Solène Huard, Amélie Brisson, et al.
European Urology|October 5, 2015
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary CarcinomasJulien Calderaro, Julien Masliah-Planchon, Wilfrid Richer, et al.
Plos One|May 24, 2013
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancerVirginie Maire, Céline Baldeyron, Marion Richardson, et al.
Haematologica|July 7, 2017
Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assayJean-Philippe Jais, Thierry Jo Molina, Philippe Ruminy, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Journal of Hematology & Oncology|September 9, 2021
HRAS is a therapeutic target in malignant chemo-resistant adenomyoepithelioma of the breastIvan Bièche, Florence Coussy, Rania El-Botty, et al.
The Journal of Pathology|June 8, 2018
The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancersSandrine Tury, Franck Assayag, Florian Bonin, et al.
The Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.
Acta Neuropathologica|March 9, 2019
SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variationMaud Blanluet, Julien Masliah-Planchon, Irina Giurgea, et al.
Pigment Cell & Melanoma Research|February 1, 2017
Nanobodies against surface biomarkers enable the analysis of tumor genetic heterogeneity in uveal melanoma patient-derived xenograftsRonan Crépin, David Gentien, Angeline Duché, et al.
BMC Cancer|June 3, 2011
Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patientsPatricia de Cremoux, Fabien Valet, David Gentien, et al.
Cancers|January 21, 2022
PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast CancerSamyuktha Suresh, Solène Huard, Amélie Brisson, et al.
European Urology|October 5, 2015
Balanced Translocations Disrupting SMARCB1 Are Hallmark Recurrent Genetic Alterations in Renal Medullary CarcinomasJulien Calderaro, Julien Masliah-Planchon, Wilfrid Richer, et al.
Plos One|May 24, 2013
TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancerVirginie Maire, Céline Baldeyron, Marion Richardson, et al.
Haematologica|July 7, 2017
Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assayJean-Philippe Jais, Thierry Jo Molina, Philippe Ruminy, et al.
Pageof 9